Abstract
Tissue polypeptide specific antigen (TPS) measures an antigenic determinant associated with human cytokeratin 18. TPS is a marker of tumor cell activity in contrast to markers related to tumor burden. The value of detecting circulating TPS lies in the early detection of recurrence by serial determinations and in the rapid assessment of the efficacy of the treatment. Pretreatment levels of TPS in patients with metastatic breast cancer are related with prognosis. Decreasing TPS levels during therapy monitoring indicate response and a fast response is correlated to favourable prognosis. Increasing TPS levels, in the presence of clinically stable disease or partial remission, predict disease progression with a considerable lead-time. Improved effectiveness in breast cancer management can be seen when TPS is used in combination with CA 15-3. When tumor marker determinations are applied in a proper way in the appropriate situation, the results can assist the oncologist. Thus monitoring of therapy in patients with metastatic breast cancer should be based upon serial TPS and CA 15-3 determinations in serum. The use of tumor marker determinations in the early follow-up interval following surgery to detect early tumor recurrence may be simpler, more sensitive and less expensive than imaging methods.
Key words: Tumor markers, TPS, Breast cancer management
Full Text
The Full Text of this article is available as a PDF (542.5 KB).
References
- 1.Steinert P.M., Roop D.R. Molecular and cellular biology of intermediate filaments. Ann. Rev. Biochem. 1988;57:593–625. doi: 10.1146/annurev.bi.57.070188.003113. [DOI] [PubMed] [Google Scholar]
- 2.Hatzfeld M., Francke W.W. Pair formation and promiscuity of cytokeratins: Formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J. Cell. Biol. 1985;101:1826–1841. doi: 10.1083/jcb.101.5.1826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Lane E.B., Alexander C.M. Use of keratin antibodies in tumor diagnosis. Cancer Biol. 1990;1:2707–2714. [PubMed] [Google Scholar]
- 4.Rydlander L., Ziegler E., Bergman T., Schöberl E., Steiner G., Bergman A-C., Zetterberg A., Marberger M., Björklund P., Skern T., Einarsson R., Jörnvall H. Molecular characterization of tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur. J. Biochem. 1996;241:309–314. doi: 10.1111/j.1432-1033.1996.00309.x. [DOI] [PubMed] [Google Scholar]
- 5.Björklund B., Einarsson R. TPS (Tissue Polypeptide Specific Antigen) in oncologic practice: A review with reference to 3000 cases of breast cancer. Tumordiagn u. Ther. 1996;17:67–73. [Google Scholar]
- 6.Mishaeli M., Klein B., Sadikov E., Bayer I., Koren R., Gal R., Rakpowsky E., Levin I., Kfir B., Schatter J., Klein T. Initial serum levels as an indicator of relapse and survival in colorectal cancer. Anticancer Res. 1998;18:2101–2106. [PubMed] [Google Scholar]
- 7.Einarsson R. Comment letter: TPS in lung cancer. Pandora. 1998;1:35–36. [Google Scholar]
- 8.Nisman B., Lafair J., Heching N., Lyass O., Baras M., Peretz T., Barak V. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850–1859. doi: 10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
- 9.Dalen A., Favier J., Baumgartner L., Hasholzner H., Bruijn H., Dombi V.H., Dobler D., Giai M., McGing P., Harlozinska A., Kainz Ch., Markowska J., Molina R., Sturgeon C., Einarsson R. CA 125 and TPS: Additive prognostic factors in ovarian cancer? Anticancer Res. 1998;18:4965–4966. [Google Scholar]
- 10.Kramer G., Steiner G.E., Madersbacher S., Stulnig T., Lang T., Marberger M. Serial tissue polypeptide specific antigen determinations in the follow-up of hormone treated carcinoma of the prostate. J. Urol. 1997;158:1446–1451. doi: 10.1016/S0022-5347(01)64239-3. [DOI] [PubMed] [Google Scholar]
- 11.ASCO Tumor Marker Panel Clinical practice guidelines for the use of tumor markers in breast cancer and colorectal cancer. J. Clin. Oncol. 1996;10:2843–2877. doi: 10.1200/JCO.1996.14.10.2843. [DOI] [PubMed] [Google Scholar]
- 12.Dnistrian A.M., Schwartz M.K., Greenberg E.J., Smith C.A., Schwartz D.C. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin. Chim. Acta. 1991;200:81–93. doi: 10.1016/0009-8981(91)90080-V. [DOI] [PubMed] [Google Scholar]
- 13.Gion M., Mione R., Nascimben O., Valsecchi M., Gatti C., Leon A., Bruscagnini G. The tumor associated antigen CA 15-3 in primary breast cancer. Evaluation of 667 cases. Br. J. Cancer. 1991;63:809–813. doi: 10.1038/bjc.1991.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Dalen A. TPS in breast cancer—A comparative study with carcinoembryonic antigen and CA 15-3. Tumor Biol. 1992;13:10–17. doi: 10.1159/000217747. [DOI] [PubMed] [Google Scholar]
- 15.Giai M., Roagna R., Ponzone R., Biglia N., Sgro L., Perona M., Sismondi P. TPS and CA 15-3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res. 1996;16:875–882. [PubMed] [Google Scholar]
- 16.Eskelinen M., Hippeläinen M., Kettunen J., Salmela E., Penttilä I., Alhava E. Clinical value of serum tumor markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; Results from a prospective study. Anticancer Res. 1994;14:699–704. [PubMed] [Google Scholar]
- 17.Molina R., Zanon G., Filella X., Moreno F., Jo J., Daniels M., Latre M.L., Gimenez N., Pahisa J., Velasco M., Ballesta A.M. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res. Treat. 1995;36:41–48. doi: 10.1007/BF00690183. [DOI] [PubMed] [Google Scholar]
- 18.Klein B., Lurie H., Levin I., Michaeli M., Faberstein M., Shapira I., Lehman JM., Hart J., Klein T. A comparative study of tumor markers of proliferation, differentiation and tumor immunology in breast cancer patients. Cancer J. 1994;7:238–240. [Google Scholar]
- 19.Aydiner A., Topusz E., Disci R., Yasasever V., Dincer M., Dincol K., Bilge N. Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol. 1994;33:181–186. doi: 10.3109/02841869409098402. [DOI] [PubMed] [Google Scholar]
- 20.Lamerz R., Leonardt A., Ehrhardt H., Lieven H. Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev. Biol. Med. 1980;1:123–135. [PubMed] [Google Scholar]
- 21.Dalen A., Linde D.L., Heering K.J., Blusse van Oud Albas A. How can treatment response be measured in breast cancer patients? Anticancer Res. 1993;13:1901–1904. [PubMed] [Google Scholar]
- 22.Schuurman J.J., Bong S.B., Einarsson R. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res. 1996;16:2169–2172. [PubMed] [Google Scholar]
- 23.Blijlevens N.M.A., Oosterhuis W.P., Oosten H.R., Mulder H.H. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res. 1995;15:2711–2716. [PubMed] [Google Scholar]
- 24.Barak V., Nisman B., Roisman I., Hubert A., Farbstein H., Baider L., Kaplan A., Halperin T., Stephanos S., Peretz T. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncol. 1997;12:17–25. [Google Scholar]
- 25.Pronk L.C., Stoter G., Putten W.L.J., Wit R. The correlation of CA 15-3 and TPS with tumor course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 1997;123:128–132. doi: 10.1007/BF01269892. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Barak V., Nisman B., Hubert A., Peretz T. TPS—prognosticator in breast cancer. Anticancer Res. 1998;18:4982–4982. [Google Scholar]
- 27.Dalen A., Heering K.J., Barak V., Peretz T., Cremaschi A., Geroni P., Gion M., Saracchini S., Molina R., Namer M., Stieber P., Sturgeon C., Leonard R.C.F., Einarsson R. Treatment response in metastatic breast cancer. A multicenter study comparing UICC criteria and tumor marker changes. The Breast. 1996;5:82–88. doi: 10.1016/S0960-9776(96)90126-5. [DOI] [Google Scholar]
- 28.Dalen A., Barak V., Cremaschi A., Gion M., Molina R., Namer M., Stieber P., Sturgeon C., Einarsson R. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int. J. Biol. Markers. 1998;13:10–15. doi: 10.1177/172460089801300103. [DOI] [PubMed] [Google Scholar]